European Pharmacopoeia to End Animal Testing for Bacterial Endotoxins by 2026

Under the new approach, manufacturers must transition to modern, validated alternatives, such as recombinant Factor C (rFC) and the monocyte activation test (MAT). These methods are not only animal-free but also offer increased consistency and scientific rigour.

Shift Away from Rabbit-Based Testing

The withdrawal of general chapter 2.6.8 (Pyrogens) from Ph. Eur. texts signals the end of a decades-long reliance on the RPT, which traditionally used rabbits to detect fever-inducing contaminants in pharmaceutical products.

From 2026, pyrogen testing will be governed by general chapter 2.6.30, which outlines a risk-based selection of suitable non-endotoxin pyrogen tests. Meanwhile, general chapter 5.1.13 (Pyrogenicity) places the responsibility on users to choose an appropriate method based on the product profile and scientific justification.

The EPC (European Pharmacopoeia Commission) has officially endorsed recombinant Factor C as one of seven approved endotoxin detection methods, positioning it as a validated synthetic alternative that avoids the use of horseshoe crab blood.

Broader Industry Implications

This regulatory change has significant implications for pharmaceutical and biopharmaceutical manufacturers, contract laboratories, and suppliers of endotoxin detection reagents. Beyond animal welfare, the move addresses growing concerns around the sustainability of horseshoe crab populations and the variability of biological reagents.

The EDQM (European Directorate for the Quality of Medicines & HealthCare) and the European Partnership for Alternative Approaches to Animal Testing (EPAA) are coordinating stakeholder engagement through a joint symposium scheduled for 25–26 February 2026 in Brussels. The event will highlight regulatory expectations, practical implementation strategies, and innovation in pyrogen testing technologies.

A Step Towards Global Harmonisation

While recombinant Cascade Reagents (rCR) are not yet included in the Ph. Eur., the EPC is encouraging data submission to support their potential adoption. This forward-looking approach reflects the broader aim of achieving global harmonisation in testing standards and fostering cross-border pharmaceutical innovation.

The phase-out strategy is aligned with Directive 2010/63/EU on animal welfare and underscores the EU’s commitment to 3Rs (Replacement, Reduction, and Refinement) principles in scientific testing.